<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03140514</url>
  </required_header>
  <id_info>
    <org_study_id>Urine chemokine monitoring</org_study_id>
    <nct_id>NCT03140514</nct_id>
  </id_info>
  <brief_title>Urine CXCL10 Chemokine Monitoring Post-renal Transplant</brief_title>
  <official_title>Urine CXCL10 Chemokine Monitoring Post-renal Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study investigators will investigate whether early treatment of allograft rejection,
      as detected by urine CXCL10-monitoring, improves outcomes in renal allograft recipients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      n.a.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 28, 2017</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Graft loss not due to death of the patient</measure>
    <time_frame>First year post-transplant</time_frame>
    <description>1-year composite outcome consisting of at least one of the primary outcomes 1 to 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biopsy-proven clinical acute rejection</measure>
    <time_frame>4-weeks up to 1-year post-transplant</time_frame>
    <description>1-year composite outcome consisting of at least one of the primary outcomes 1 to 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subclinical T-cell mediated rejection in 1-year surveillance biopsy defined by t&gt;0 and/or v&gt;0</measure>
    <time_frame>First year post-transplant</time_frame>
    <description>1-year composite outcome consisting of at least one of the primary outcomes 1 to 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interstitial fibrosis / tubular atrophy with inflammation (IFTA+i defined by the Mayo Clinic criteria) in 1-year surveillance biopsy</measure>
    <time_frame>First year post-transplant</time_frame>
    <description>1-year composite outcome consisting of at least one of the primary outcomes 1 to 4</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessed by microvascular inflammation at 1-year (ptc, g, c4d, cg)</measure>
    <time_frame>First year post-transplant</time_frame>
    <description>Microvascular inflammation at 1-year (ptc, g, c4d, cg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessed by development of IFTA from implantation to 1-year (∆ ci, ct, cv)</measure>
    <time_frame>First year post-transplant</time_frame>
    <description>Development of IFTA from implantation to 1-year (∆ ci, ct, cv)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessed by number of days from transplantation to biopsy-proven clinical acute rejection</measure>
    <time_frame>First year post-transplant</time_frame>
    <description>number of days from transplantation to biopsy-proven clinical acute rejection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessed by Proteinuria &gt;500mg/day at 6- and 12-months post-transplant</measure>
    <time_frame>First year post-transplant</time_frame>
    <description>Proteinuria &gt;500mg/day at 6- and 12-months post-transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by total number of biopsies, indication for biopsy and CXCL10-triggered biopsies within the first year post-transplant</measure>
    <time_frame>First year post-transplant</time_frame>
    <description>total number of biopsies, indication for biopsy and CXCL10-triggered biopsies within the first year post-transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by biopsy-related complications within the first year post-transplant</measure>
    <time_frame>First year post-transplant</time_frame>
    <description>biopsy-related complications within the first year post-transplant biopsy-related complications within the first year post-transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by immunosuppression-related complications as infections and cancer within the first year post-transplant</measure>
    <time_frame>First year post-transplant</time_frame>
    <description>immunosuppression-related complications as infections and cancer within the first year post-transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft and its cause</measure>
    <time_frame>yearly up to 10 years</time_frame>
    <description>Long-term outcome Graft and its cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death and its cause</measure>
    <time_frame>yearly up to 10 years</time_frame>
    <description>Long-term outcome Death and its cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Allograft function measured by creatinine and eGFR</measure>
    <time_frame>yearly up to 10 years</time_frame>
    <description>Long-term outcome Allograft function measured by creatinine and epidermal growth factor receptor (eGFR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proteinuria</measure>
    <time_frame>yearly up to 10 years</time_frame>
    <description>Long-term outcome Proteinuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biopsy-proven rejection</measure>
    <time_frame>yearly up to 10 years</time_frame>
    <description>Long-term outcome Biopsy-proven rejection</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">178</enrollment>
  <condition>Renal Transplant Rejection</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Urine CXCL10-chemokine levels will be monitored at specific time points post-transplant. Sustained elevated levels will trigger performance of a renal allograft biopsy. Any rejection will be treated. Rejection treatment according to clinical standard-of-care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Urine CXCL10-chemokine levels will be monitored at specific time points post-transplant, but the values are concealed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rejection treatment according to clinical standard-of-care</intervention_name>
    <description>Standard-of-care treatment is based on the severity and phenotype of biopsy-proven rejection</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All consenting adult (age&gt;=18) renal allograft recipients

        Exclusion Criteria:

          -  Human Leucocyte Antigen (HLA) -identical living donor transplantation

          -  Primary non-function

          -  Participation in immunosuppression interventional trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Schaub, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefan Schaub, MD, MSc</last_name>
    <phone>+41(0)61 2652525 Zentrale</phone>
    <email>stefan.schaub@usb.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Basel, Transplantation Immunology &amp; Nephrology</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Schaub, MD MSc</last_name>
      <phone>+41 61 265 45 33</phone>
      <email>stefan.schaub@usb.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2017</study_first_submitted>
  <study_first_submitted_qc>May 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2017</study_first_posted>
  <last_update_submitted>September 28, 2017</last_update_submitted>
  <last_update_submitted_qc>September 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Urine chemokine monitoring</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

